Alnylam Licenses Kreutzer-Limmer IP to Dharmacon
Alnylam Pharmaceuticals said this week that it has granted Dharmacon a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family.
Specific terms of the deal were not disclosed.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.